Haizheng Pharmaceutical announced that the second extraordinary shareholders' meeting will be held on July 20, 2026 to consider the proposal to sign an exclusive product license and cooperation agreement with Etiya Pharmaceutical Co., Ltd. The company plans to introduce chemical-class 1 TISA-818 drug delivery formulations in mainland China, Hong Kong and Macau. It is required to pay 45 million yuan for payment at the head of state, up to 100 million yuan for development milestones, up to 50 million yuan for each approval for new indications for marketing, and a cumulative sales milestone incentive of up to 200 million yuan. This cooperation may enrich the company's innovative drug pipeline and enhance competitiveness, but there are risks such as product approval, payment amounts, and early termination of agreements.

Haizheng Pharmaceutical announced that the second extraordinary shareholders' meeting will be held on July 20, 2026 to consider the proposal to sign an exclusive product license and cooperation agreement with Etiya Pharmaceutical Co., Ltd. The company plans to introduce chemical-class 1 TISA-818 drug delivery formulations in mainland China, Hong Kong and Macau. It is required to pay 45 million yuan for payment at the head of state, up to 100 million yuan for development milestones, up to 50 million yuan for each approval for new indications for marketing, and a cumulative sales milestone incentive of up to 200 million yuan. This cooperation may enrich the company's innovative drug pipeline and enhance competitiveness, but there are risks such as product approval, payment amounts, and early termination of agreements.